- Home
- SUUN vs UNCY Comparison
SUUN vs UNCY Comparison
Compare SUUN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- UNCY
- Stock Information
- Founded
- SUUN 2013
- UNCY 2016
- Country
- SUUN Canada
- UNCY United States
- Employees
- SUUN N/A
- UNCY N/A
- Industry
- SUUN
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- SUUN
- UNCY Health Care
- Exchange
- SUUN Nasdaq
- UNCY Nasdaq
- Market Cap
- SUUN 75.1M
- UNCY 74.2M
- IPO Year
- SUUN N/A
- UNCY 2021
- Fundamental
- Price
- SUUN $1.87
- UNCY $4.63
- Analyst Decision
- SUUN Strong Buy
- UNCY Strong Buy
- Analyst Count
- SUUN 2
- UNCY 5
- Target Price
- SUUN $5.00
- UNCY $55.20
- AVG Volume (30 Days)
- SUUN 243.4K
- UNCY 510.5K
- Earning Date
- SUUN 11-13-2025
- UNCY 11-12-2025
- Dividend Yield
- SUUN N/A
- UNCY N/A
- EPS Growth
- SUUN N/A
- UNCY N/A
- EPS
- SUUN N/A
- UNCY N/A
- Revenue
- SUUN $30,451,073.00
- UNCY N/A
- Revenue This Year
- SUUN $86.31
- UNCY N/A
- Revenue Next Year
- SUUN $24.16
- UNCY $4,481.14
- P/E Ratio
- SUUN N/A
- UNCY N/A
- Revenue Growth
- SUUN N/A
- UNCY N/A
- 52 Week Low
- SUUN $1.23
- UNCY $3.40
- 52 Week High
- SUUN $6.43
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- SUUN 55.74
- UNCY 61.71
- Support Level
- SUUN $1.46
- UNCY $3.72
- Resistance Level
- SUUN $1.68
- UNCY $4.80
- Average True Range (ATR)
- SUUN 0.11
- UNCY 0.24
- MACD
- SUUN 0.01
- UNCY 0.07
- Stochastic Oscillator
- SUUN 93.02
- UNCY 75.00
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.